Evidence map›Paper›PMID 32281925›Full record

ArticleBlood transfusion = Trasfusione del sangue2020

Cord blood-derived platelet concentrates as starting material for new therapeutic blood components prepared in a public cord blood bank: from product development to clinical application.

Dinara Samarkanova, Luciano Rodríguez, Joaquim Vives, Ruth Coll, Elisabet Tahull, Carmen Azqueta, Elena Valdivia, Margarita Codinach, Elisenda Farssac, Jesus Gaitan and 2 more

Open access · greenAbstract read
In one paragraph

Article in Blood transfusion = Trasfusione del sangue, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Cord Blood-Derived Platelet Gel in Wound Healing: From Biological Rationale to Clinical Application.Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Dinara Samarkanova"Banc de Sang i Teixits", Barcelona, Spain.
Luciano Rodríguez"Banc de Sang i Teixits", Barcelona, Spain.
Joaquim Vives"Banc de Sang i Teixits", Barcelona, Spain.
Ruth Coll"Banc de Sang i Teixits", Barcelona, Spain.
Elisabet Tahull"Banc de Sang i Teixits", Barcelona, Spain.
Carmen Azqueta"Banc de Sang i Teixits", Barcelona, Spain.
Elena Valdivia"Banc de Sang i Teixits", Barcelona, Spain.
Margarita Codinach"Banc de Sang i Teixits", Barcelona, Spain.
Elisenda Farssac"Banc de Sang i Teixits", Barcelona, Spain.
Jesus GaitanDiabetic Foot Unit, Department of Angiology, Vascular and Endovascular Surgery, "Santa Creu i Sant Pau" Hospital, Barcelona, Spain.
Jose R EscuderoDiabetic Foot Unit, Department of Angiology, Vascular and Endovascular Surgery, "Santa Creu i Sant Pau" Hospital, Barcelona, Spain.
Sergio Querol"Banc de Sang i Teixits", Barcelona, Spain.
Banc de Sang i Teixits · ESUniversitat Autònoma de Barcelona · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere are many advantages to using cord blood (CB) as a source of therapeutic platelet and plasma derivatives for regenerative medicine. These include availability, universal use, young donor source, and virally safe biological material, rich in tissue regenerative factors. MATERIALS AND

methodsWe aimed to validate a bioprocess design for the production of cord blood-derived platelet concentrates (CBPC) in a public Cord Blood Bank (CBB). CBPC was defined as a product of 10±5 mL, 1,000±200×10

resultsAfter processing, 84% of the products fulfilled the acceptance criteria. Final products contained 1,017±149×10 DISCUSSION: We designed and validated a highly reproducible, closed system method to manufacture high quality CBPC suitable for clinical applications using CB units not suitable for transplantation in a public CBB.

Indexed as

Blood BanksBlood PlateletsDiabetic FootFetal BloodHumansPlatelet-Derived Growth FactorPlatelet-Rich PlasmaTransforming Growth Factor beta1Platelet-Derived Growth Factorplatelet-derived growth factor ABTGFB1 protein, humanTransforming Growth Factor beta1

Identifiers

PMID32281925
PMCPMC7250694
OpenAlexW3015812916

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.